Canada Cardiac Marker Testing Market (2026-2031)
The Canada Cardiac Marker Testing Market was valued at $24.8 Million in 2026 and projected to reach to $37 Million by 2031, representing a compound annual growth rate of 8.3%. Canada's cardiac marker testing market is positioned for steady growth driven by an aging population and rising cardiovascular disease incidence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada Cardiac Marker Testing Market Trends and Insights
- This growth trajectory reflects Canada's aging population, increasing prevalence of cardiovascular diseases, and rising demand for rapid diagnostic solutions in both hospital and point-of-care settings.
- Canada's healthcare infrastructure and emphasis on early disease detection are driving adoption of advanced cardiac biomarker assays across clinical laboratories and emergency departments. The Canadian market benefits from strong healthcare spending, regulatory support for diagnostic innovation, and integration of cardiac marker testing into standard clinical protocols.
- Between 2026 and 2031, Canada is expected to see expanded utilization of high-sensitivity troponin assays and multiplex testing platforms.
- Canada's position within North America positions it as a key market for cardiac diagnostics, supported by partnerships between diagnostic manufacturers and Canadian healthcare providers seeking to improve patient outcomes and reduce hospital readmission rates..
Key Market Statistics
- CAGR (2026-2031) 8.3% CAGR
- Market Size, 2026 ~USD 24.8 Million
- Forecast, 2031 ~USD 37 Million
- Country Canada
Canada Cardiac Marker Testing Market Overview
Market Size & Growth :
Canada's cardiac marker testing market is valued at $24.8 million in 2026 and is projected to reach $37.0 million by 2031, with a CAGR of 8.3%, outpacing many developed markets in adoption velocity.
Aging Population Driver :
Canada's demographic shift toward an older population is significantly increasing cardiovascular disease prevalence, driving demand for early detection and rapid diagnostic cardiac marker tests across healthcare facilities.
Healthcare System Integration :
Canada's publicly funded healthcare system is increasingly adopting point-of-care cardiac marker testing to reduce emergency department wait times and improve patient outcomes in both urban and rural settings.
Regional Expansion Opportunity :
Growing investment in diagnostic infrastructure across Canadian provinces, particularly in remote and underserved regions, is creating new opportunities for cardiac marker testing deployment and market penetration.
Canada Cardiac Marker Testing Market Dynamics
- The Canadian healthcare system's emphasis on rapid diagnostics and cost-effective care pathways is accelerating adoption of advanced cardiac biomarker assays in both hospital laboratories and point-of-care settings.
- Provincial health authorities are increasingly prioritizing cardiac care infrastructure investments, supporting market expansion. The 8.3% CAGR reflects Canada's unique healthcare dynamics, including universal coverage driving standardized testing protocols and growing demand for faster turnaround times in emergency departments.
- Technological advancements in high-sensitivity troponin assays and multiplex testing platforms are gaining traction, while partnerships between diagnostic manufacturers and Canadian healthcare providers are strengthening market accessibility across provinces..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- Canada's cardiac marker testing market is valued at $24.8 million in 2026 and will reach $37.0 million by 2031, growing at 8.3% CAGR.
- Canada's aging demographic and rising cardiovascular disease prevalence are primary drivers of market expansion through 2031.
- High-sensitivity troponin assays and multiplex testing platforms are gaining adoption across Canada's hospital and emergency care settings.
- Canada's robust healthcare infrastructure and diagnostic innovation support create favorable conditions for market growth and manufacturer partnerships.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
Canada Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
CANADA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC INSTITUTES | 27.7 | 27.6 | 29.4 | 31.4 | 33.7 | 36.3 | 39.1 | 42.3 | 7.5 |
| LABORATORY TESTING FACILITIES | 158.2 | 155.8 | 164.5 | 174 | 184.8 | 197 | 210.4 | 224.9 | 6.5 |
| POINT-OF-CARE TESTING | 56.1 | 56.3 | 60.7 | 65.5 | 70.9 | 77.1 | 84 | 91.7 | 8.6 |
| TOTAL | 242 | 239.7 | 254.6 | 270.9 | 289.4 | 310.3 | 333.6 | 358.9 | 7.1 |
Target Audience
- Diagnostic Equipment Manufacturers : Need Canadian market data to develop localized product strategies, understand provincial procurement processes, and identify opportunities for cardiac marker testing platform expansion across Canadian healthcare facilities.
- Healthcare System Administrators : Require market intelligence to justify investments in cardiac diagnostic infrastructure, benchmark testing volumes against national trends, and optimize emergency department efficiency through rapid cardiac marker protocols.
- Clinical Laboratory Directors : Seek insights on testing demand forecasts, emerging biomarker technologies, and best practices for implementing high-sensitivity troponin assays to improve patient outcomes and operational efficiency in Canadian labs.
- Medical Device Investors & Consultants : Need comprehensive Canadian market analysis to evaluate investment opportunities, assess competitive landscapes, and identify acquisition targets in the cardiac diagnostics sector with growth potential.
- Healthcare Policy & Regulatory Bodies : Require market data to inform reimbursement policies, diagnostic guidelines, and healthcare resource allocation decisions that support equitable access to cardiac marker testing across Canadian provinces.
Key Companies in the Canada Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Market-Specific Sizing & Forecasts : Access precise Canadian market valuations ($24.8M in 2026, $37M in 2031) with country-specific CAGR of 8.3%, enabling accurate financial planning and investment decisions tailored to Canada's healthcare landscape.
- Provincial Healthcare Insights : Understand how Canada's provincial healthcare systems are adopting cardiac marker testing, including regulatory requirements, reimbursement structures, and procurement patterns unique to Canadian public health authorities.
- Competitive Positioning Strategy : Identify market gaps and competitive opportunities specific to Canada's diagnostic sector, including unmet needs in rural regions and emerging demand for rapid turnaround testing in emergency departments.
- Growth Driver Analysis : Leverage detailed insights on Canada's aging demographics, cardiovascular disease prevalence trends, and healthcare system priorities to align product development and market entry strategies with local demand drivers.
- Investment & Partnership Opportunities : Discover strategic partnership potential with Canadian healthcare providers, diagnostic laboratories, and provincial health systems to accelerate market penetration and establish sustainable competitive advantages.
Frequently asked questions
What is the current size of Canada's cardiac marker testing market?
Canada's cardiac marker testing market is valued at $24.8 million in 2026 and is expected to grow to $37.0 million by 2031.
What is the projected growth rate for Canada's cardiac marker testing market?
Canada's cardiac marker testing market is projected to grow at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2031.
What factors are driving growth in Canada's cardiac marker testing market?
Key drivers include Canada's aging population, increasing cardiovascular disease prevalence, strong healthcare spending, regulatory support for diagnostic innovation, and integration of cardiac testing into standard clinical protocols.
Which cardiac marker tests are most commonly used in Canada?
High-sensitivity troponin assays and multiplex testing platforms are increasingly adopted across Canada's hospital and emergency care settings for rapid and accurate cardiac diagnosis.
How does Canada's market compare to other North American countries?
Canada represents a significant segment of the North American cardiac marker testing market, supported by universal healthcare access, strong diagnostic infrastructure, and clinical emphasis on early cardiovascular disease detection.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report